Clinical efficacy and safety evaluation of short-term intensive insulin as-part injection Novorapid therapy hepatogenic diabetes with liver decom-pensation / 中国现代医生

ABSTRACT

Objective To investigate the efficacy and safety of short-term intensive insulin aspart injection (Novo-rapid) therapy hepatogenic diabetes with liver decompensation patients. Mothods A two weeks randomized,open-la-bel, confrolled trial comparing Novolin 30R with short-term intensive Novorapid was performed. 100 cases were ran-domly divided into treatment group and control group,50 cases for each. The two groups were given traditional medical treatment, while the control group received Novolin 30R twice per day,the treatment group received Novorapid thrice per-day. The indicators such as FBG,2hPG,HbA1c, Ins,C-P,hypoglycemia incidence and liver function (ALT, AST, ALB and TBIL)were evaluated,β-cell function(HOMA-β)and insulin resistance index(HOMA-IR) were calculated. The changes of above indicators before and after therapy were compared between two groups. Results After the treat-ment,the FBG,2hPG,HbA1c,HOMA-IR and liver function of two groups were respectively lower than those before(P<0.05),hypoglycemia incidence of the treatment group were lower than those of the control group(P<0.05),while the differences between two groups was significant(P<0.05). Conclusion Short-term intensive Novorapid therapy for hep-atogenic diabetes with liver decompensation can reduce FBG and 2hPG,reduce the incidence of hypoglycemia, im-prove liver function,and also reduce insulin resistance. Meanwhile,the therapy is a more effective and safer therapy.